Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Amortization of Deferred Charges: 2011-2014

Historic Amortization of Deferred Charges for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Dec 2014 value amounting to -$720.

  • Lineage Cell Therapeutics' Amortization of Deferred Charges rose 99.91% to -$720 in Q4 2014 from the same period last year, while for Dec 2014 it was -$840,086, marking a year-over-year increase of 8.19%. This contributed to the annual value of $22,000 for FY2023, which is N/A change from last year.
  • Lineage Cell Therapeutics' Amortization of Deferred Charges amounted to -$720 in Q4 2014, which was down 157.14% from -$280 recorded in Q1 2014.
  • Over the past 5 years, Lineage Cell Therapeutics' Amortization of Deferred Charges peaked at -$280 during Q1 2014, and registered a low of -$790,118 during Q4 2013.
  • Over the past 3 years, Lineage Cell Therapeutics' median Amortization of Deferred Charges value was -$37,898 (recorded in 2012), while the average stood at -$112,706.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Amortization of Deferred Charges crashed by 703.32% in 2013, and later soared by 99.91% in 2014.
  • Over the past 4 years, Lineage Cell Therapeutics' Amortization of Deferred Charges (Quarterly) stood at -$48,746 in 2011, then tumbled by 101.77% to -$98,357 in 2012, then tumbled by 703.32% to -$790,118 in 2013, then surged by 99.91% to -$720 in 2014.
  • Its Amortization of Deferred Charges stands at -$720 for Q4 2014, versus -$280 for Q1 2014 and -$790,118 for Q4 2013.